Sökning: (L773:1932 6203) srt2:(2015-2019) pers:(Nilsson Peter)
> (2019) >
Plasma protein prof...
Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment
-
- Bedri, Sahl Khalid (författare)
- Karolinska Institutet
-
- Nilsson, Ola B. (författare)
- Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Karolinska Inst, Ctr Mol Med, Stockholm, Sweden.;Advice Foretagsassistans & Stockholm AB, TCER AB, Stockholm, Sweden.
-
- Fink, Katharina (författare)
- Karolinska Institutet
-
visa fler...
-
- Månberg, Anna (författare)
- KTH,Affinitets-proteomik,Sch Engn Sci Chem Biotechnol & Hlth, Affin Prote, SciLifeLab, Stockholm, Sweden.
-
- Hamsten, Carl (författare)
- Karolinska Institutet
-
- Ayoglu, Burcu (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Sch Engn Sci Chem Biotechnol & Hlth, Affin Prote, SciLifeLab, Stockholm, Sweden.
-
- Manouchehrinia, Ali (författare)
- Karolinska Institutet
-
- Nilsson, Peter (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Sch Engn Sci Chem Biotechnol & Hlth, Affin Prote, SciLifeLab, Stockholm, Sweden.
-
- Olsson, Tomas (författare)
- Karolinska Institutet
-
- Hillert, Jan (författare)
- Karolinska Institutet
-
- Grönlund, Hans (författare)
- Karolinska Institutet
-
- Glaser, Anna (författare)
- Karolinska Institutet
-
visa färre...
-
Karolinska Institutet Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden;Karolinska Inst, Ctr Mol Med, Stockholm, Sweden.;Advice Foretagsassistans & Stockholm AB, TCER AB, Stockholm, Sweden. (creator_code:org_t)
- 2019-05-29
- 2019
- Engelska.
-
Ingår i: PLOS ONE. - : PUBLIC LIBRARY SCIENCE. - 1932-6203. ; 14:5
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://journals.plo...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Multiple sclerosis (MS) treatment options have improved significantly over the past decades, but the consequences of MS can still be devastating and the needs for monitoring treatment surveillance are considerable. In the current study we used affinity proteomics technology to identify potential biomarkers which could ultimately be used to as facilitate treatment decisions. We profiled the intra-individual changes in the levels of 59 target proteins using an antibody suspension bead array in serial plasma samples from 44 MS patients during treatment with natalizumab followed by fingolimod. Nine proteins showed decreasing plasma levels during natalizumab treatment, with PEBP1 and RTN3 displaying the most significant changes. Protein levels remained stable during fingolimod treatment for both proteins. The decreasing PEBP1 levels during natalizumab treatment could be validated using ELISA and replicated in an independent cohort. These results support the use of this technology as a high throughput method of identifying potentially useful biomarkers of MS treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
PLOS ONE
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Bedri, Sahl Khal ...
-
Nilsson, Ola B.
-
Fink, Katharina
-
Månberg, Anna
-
Hamsten, Carl
-
Ayoglu, Burcu
-
visa fler...
-
Manouchehrinia, ...
-
Nilsson, Peter
-
Olsson, Tomas
-
Hillert, Jan
-
Grönlund, Hans
-
Glaser, Anna
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Klinisk laborato ...
- Artiklar i publikationen
-
PLOS ONE
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet